Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.82 AUD | -1.05% | -2.69% | -24.63% |
05-28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
05-27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.63% | 1.6B | |
+48.53% | 780B | |
+41.80% | 627B | |
-6.37% | 353B | |
+20.93% | 334B | |
+8.21% | 296B | |
+17.94% | 244B | |
-1.02% | 217B | |
+11.46% | 214B | |
+4.40% | 161B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- US FDA Accepts Neuren Pharmaceuticals' Licensed Drug for Use in Rhett Syndrome; Shares Rise 4%